Anastasios Kartas, Andreas S Papazoglou, Dimitrios V Moysidis, Stefanos Despotopoulos, Amalia Baroutidou, Diamantis Kosmidis, Athanasios Koutsakis, Sotiria Liori, Sotiria Apostolopoulou, Alexandra Frogoudaki, Afrodite Tzifa, Apostolos Galatas, Georgios Alexandridis, Efstathios Spiridonidis, Ioannis Doundoulakis, Efstratios Karagiannidis, Haralambos Karvounis, Antonios Ziakas, George Giannakoulas
BACKGROUND: Adults with congenital heart disease (ACHD) and atrial arrhythmias (AA) face an increased risk of thromboembolic events. Limited data exist on the use of non-vitamin K oral anticoagulants for thromboprophylaxis in ACHD. We aimed to assess the effectiveness and safety of apixaban in ACHD patients with AA. METHODS: PROTECT-AR (NCT03854149) was a prospective, multicenter, observational study conducted from 2019 to 2023. ACHD patients with atrial fibrillation, atrial flutter, or intra-atrial re-entrant tachycardia on routine apixaban treatment were included...
March 31, 2024: International Journal of Cardiology